The ABCC4 membrane transporter modulates platelet aggregation

Blood

Volumn 126, Issue 20, 2015, Pages 2307-2319

  Cheepala, Satish B ^a   Pitre, Aaron ^a   Fukuda, Yu ^a   Takenaka, Kazumasa ^a   Zhang, Yuanyuan ^a   Wang, Yao ^a   Frase, Sharon ^a   Pestina, Tamara ^a   Gartner, T Kent ^b   Jackson, Carl ^a   Schuetz, John D ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF MEMPHIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; COLLAGEN RECEPTOR; COLLAGEN RECEPTOR GPVI; CYCLIC AMP; FERRIC CHLORIDE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; PHOSPHODIESTERASE; UNCLASSIFIED DRUG; 9-(2-HYDROXY-3-NONYL)ADENINE; ABCC4 PROTEIN, HUMAN; ABCC4 PROTEIN, MOUSE; ADENINE; MULTIDRUG RESISTANCE PROTEIN; PHOSPHODIESTERASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOTINYLATION; BLEEDING TIME; BLOOD CLOTTING; BLOOD VESSEL INJURY; CAROTID ARTERY INJURY; CELL MEMBRANE; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SUPERRESOLUTION MICROSCOPY; THROMBOCYTE AGGREGATION; VASCULARIZATION; ANALOGS AND DERIVATIVES; ANIMAL; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; THROMBOCYTE; THROMBOSIS;

ADENINE; ANIMALS; BLOOD PLATELETS; CYCLIC AMP; HUMANS; MICE; MICE, KNOCKOUT; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PLATELET AGGREGATION; THROMBOSIS;

EID: 84949009510     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-08-595942     Document Type: Article

References (40)

1. Lacroix-Pépin N, Danyod G, Krishnaswamy N, et al. The multidrug resistance-associated protein 4 (MRP4) appears as a functional carrier of prostaglandins regulated by oxytocin in the bovine endometrium. Endocrinology. 2011;152(12): 4993-5004.
2. Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem. 2007;76:481-511.
3. Haslam RJ, Dickinson NT, Jang EK. Cyclic nucleotides and phosphodiesterases in platelets. Thromb Haemost. 1999;82(2):412-423.
4. Jedlitschky G, Tirschmann K, Lubenow LE, et al. The nucleotide transporter MRP4 (ABCC4) is highly expressed in human platelets and present in dense granules, indicating a role in mediator storage. Blood. 2004;104(12): 3603-3610.
5. Jedlitschky G, Cattaneo M, Lubenow LE, et al. Role of MRP4 (ABCC4) in platelet adenine nucleotide-storage: evidence from patients with delta-storage pool deficiencies. Am J Pathol. 2010;176(3):1097-1103.
6. Lewandrowski U, Wortelkamp S, Lohrig K, et al. Platelet membrane proteomics: a novel repository for functional research. Blood. 2009;114(1): e10-e19.
7. Abla N, Chinn LW, Nakamura T, et al. The human multidrug resistance protein 4 (MRP4, ABCC4): functional analysis of a highly polymorphic gene. J Pharmacol Exp Ther. 2008; 325(3):859-868.
8. Krishnamurthy P, Schwab M, Takenaka K, et al. Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. Cancer Res. 2008;68(13):4983-4989.
9. Fukuda Y, Takenaka K, Sparreboom A, et al. Human immunodeficiency virus protease inhibitors interact with ATP binding cassette transporter 4/multidrug resistance protein 4: a basis for unanticipated enhanced cytotoxicity. Mol Pharmacol. 2013;84(3):361-371.
10. Leggas M, Adachi M, Scheffer GL, et al. Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol. 2004; 24(17):7612-7621.
11. Guerrero JA, Kyei M, Russell S, et al. Visualizing the von Willebrand factor/glycoprotein Ib-IX axis with a platelet-type von Willebrand disease mutation. Blood. 2009; 114(27):5541-5546.
12. Cheepala SB, Bao J, Nachagari D, et al. Crucial role for phylogenetically conserved cytoplasmic loop 3 in ABCC4 protein expression. J Biol Chem. 2013;288(31):22207-22218.
13. Wall JE, Buijs-Wilts M, Arnold JT, et al. A flow cytometric assay using mepacrine for study of uptake and release of platelet dense granule contents. Br J Haematol. 1995;89(2): 380-385.
14. Dütting S, Bender M, Nieswandt B. Platelet GPVI: a target for antithrombotic therapy?! Trends Pharmacol Sci. 2012;33(11):583-590.
15. Schrör K, Bretschneider E, Fischer K, et al. Thrombin receptors in vascular smooth muscle cells - function and regulation by vasodilatory prostaglandins. Thromb Haemost. 2010;103(5): 884-890.
16. Sugiyama T, Okuma M, Ushikubi F, Sensaki S, Kanaji K, Uchino H. A novel platelet aggregating factor found in a patient with defective collageninduced platelet aggregation and autoimmune thrombocytopenia. Blood. 1987;69(6): 1712-1720.
17. Chen H, Locke D, Liu Y, Liu C, Kahn ML. The platelet receptor GPVI mediates both adhesion and signaling responses to collagen in a receptor density-dependent fashion. J Biol Chem. 2002; 277(4):3011-3019.
18. Wonerow P, Obergfell A, Wilde JI, et al. Differential role of glycolipid-enriched membrane domains in glycoprotein VI- and integrin-mediated phospholipase Cgamma2 regulation in platelets. Biochem J. 2002;364(Pt 3):755-765.
19. Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? Blood. 2003;102(2):449-461.
20. Walter U, Eigenthaler M, Geiger J, Reinhard M. Role of cyclic nucleotide-dependent protein kinases and their common substrate VASP in the regulation of human platelets. Adv Exp Med Biol. 1993;344:237-249.
21. Gambaryan S, Kobsar A, Rukoyatkina N, et al. Thrombin and collagen induce a feedback inhibitory signaling pathway in platelets involving dissociation of the catalytic subunit of protein kinase A from an NFkappaB-IkappaB complex. J Biol Chem. 2010;285(24): 18352-18363.
22. Sinha C, Ren A, Arora K, et al. Multi-drug resistance protein 4 (MRP4)-mediated regulation of fibroblast cell migration reflects a dichotomous role of intracellular cyclic nucleotides. J Biol Chem. 2013;288(6):3786-3794.
23. Cheepala SB, Sukthankar M, Schuetz JD. MRP4 (ABCC4). In: Ishikawa T, Kim RB, König J, eds. Pharmacogenomics of Human Drug Transporters. Hoboken, NJ: John Wiley & Sons, Inc.; 2013: 365-385.
24. Takenaka K, Morgan JA, Scheffer GL, et al. Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution. Cancer Res. 2007;67(14): 6965-6972.
25. Reid G, Wielinga P, Zelcer N, et al. Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol. 2003; 63(5):1094-1103.
26. Xie M, Rich TC, Scheitrum C, Conti M, Richter W. Inactivation of multidrug resistance proteins disrupts both cellular extrusion and intracellular degradation of cAMP. Mol Pharmacol. 2011; 80(2):281-293.
27. Schwarz UR, Walter U, Eigenthaler M. Taming platelets with cyclic nucleotides. Biochem Pharmacol. 2001;62(9):1153-1161.
28. Margarucci L, Roest M, Preisinger C, et al. Collagen stimulation of platelets induces a rapid spatial response of cAMP and cGMP signaling scaffolds. Mol Biosyst. 2011;7(7):2311-2319.
29. Lewandrowski U, Zahedi RP, Moebius J, Sickmann A. [Functional proteome analysis of human platelets]. Hamostaseologie. 2007;27(4): 241-245.
30. Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. J Clin Invest. 2004;113(3):340-345.
31. Zhang W, Colman RW. Thrombin regulates intracellular cyclic AMP concentration in human platelets through phosphorylation/activation of phosphodiesterase 3A. Blood. 2007;110(5): 1475-1482.
32. Meacci E, Taira M, Moos M Jr, et al. Molecular cloning and expression of human myocardial cGMP-inhibited cAMP phosphodiesterase. Proc Natl Acad Sci USA. 1992;89(9):3721-3725.
33. Aszódi A, Pfeifer A, Ahmad M, et al. The vasodilatorstimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonistinduced platelet aggregation, but is dispensable for smooth muscle function. EMBO J. 1999;18(1):37-48.
34. Loyau S, Dumont B, Ollivier V, et al. Platelet glycoprotein VI dimerization, an active process inducing receptor competence, is an indicator of platelet reactivity. Arterioscler Thromb Vasc Biol. 2012;32(3):778-785.
35. Takayama H, Hosaka Y, Nakayama K, et al. A novel antiplatelet antibody therapy that induces cAMP-dependent endocytosis of the GPVI/Fc receptor gamma-chain complex. J Clin Invest. 2008;118(5):1785-1795.
36. Cheepala S, Hulot JS, Morgan JA, et al. Cyclic nucleotide compartmentalization: contributions of phosphodiesterases and ATP-binding cassette transporters. Annu Rev Pharmacol Toxicol. 2013; 53:231-253.
37. Li C, Krishnamurthy PC, Penmatsa H, et al. Spatiotemporal coupling of cAMP transporter to CFTR chloride channel function in the gut epithelia. Cell. 2007;131(5):940-951.
38. Kato K, Kanaji T, Russell S, et al. The contribution of glycoprotein VI to stable platelet adhesion and thrombus formation illustrated by targeted gene deletion. Blood. 2003;102(5):1701-1707.
39. Poole A, Gibbins JM, Turner M, et al. The Fc receptor gamma-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen. EMBO J. 1997;16(9):2333-2341.
40. Sudo T, Ito H, Kimura Y. Phosphorylation of the vasodilator-stimulated phosphoprotein (VASP) by the anti-platelet drug, cilostazol, in platelets. Platelets. 2003;14(6):381-390.